Renu Regunathan-Shenk, MD
Nephrology · Fairfax, VANPI 1457641888
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,925 of the $5,869 with a category attached, or 83.9%. 10 manufacturers reported payments, led by GSK at 49.8% of the total. Reporting peaked in 2022 at $3,068 and has fallen 83.7% since, to $499 in 2025.
Across 22 payments — averaging $266.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- Travere Therapeutics, Inc.$2K
- ANI Pharmaceuticals, Inc.$264
- Bayer$130
- Calliditas Therapeutics US Inc.$125
- Otsuka America Pharmaceutical, Inc.$119
- plus $245 from 4 others
Across 7 payments — averaging $2324.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Travere Therapeutics, Inc.$16K
What the payments were for
- Consulting fees$4,92584%
- Food & beverage$82114%
- Education$1222%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 1 | $2,925 |
| Travere Therapeutics, Inc. | 7 | $2,061 |
| ANI Pharmaceuticals, Inc. | 3 | $264 |
| Bayer | 2 | $130 |
| Calliditas Therapeutics US Inc. | 1 | $125 |
| Otsuka America Pharmaceutical, Inc. | 1 | $119 |
| Abbott | 1 | $98 |
| Novo Nordisk | 2 | $66 |
| Novartis | 3 | $56 |
| Akebia Therapeutics Inc | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BENLYSTA$2,925
- PURIFIED CORTROPHIN GEL$245
- TARPEYO$125
- Kerendia$114
How this compares
$5,869 in reported general payments places this provider in the 85th percentile of 298 nephrology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nifedipine ErNifedipine | 20 | $393 |
| Bumetanide | 21 | $335 |
| Torsemide | 16 | $327 |
| Chlorthalidone | 11 | $315 |
| Clonidine Hcl | 18 | $143 |
| Spironolactone | 15 | $97 |
| Losartan Potassium | 15 | $93 |
| Amlodipine Besylate | 13 | $72 |
| Allopurinol | 12 | $4 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Fairfax
- Reza ZonoziFairfax$262K
- Renuka SothinathanFairfax$68K
- Ali AssefiFairfax$64K
- Kinjal PatelFairfax$31K
- Paul ModlingerFairfax$18K
- Magnus IkhinmwinFairfax$11K
- Ranjit CheriyanFairfax$4K
- Ramon MendezWoodbridge$791K
- Sandeep MagoonNorfolk$204K
- Thomas McCuneNorfolk$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.